Registro:

Referencias:

• Ezzat, S., Zheng, L., Zhu, X.F., Wu, G.E., Asa, S.L., Targeted expression of a human pituitary tumor-derived isoform of FGF receptor-4 recapitulates pituitary tumorigenesis (2002) J Clin Invest, 109, pp. 69-78
• McAndrew, J., Paterson, A.J., Asa, S.L., McCarthy, K.J., Kudlow, J.E., Targeting of transforming growth factor-alpha expression to pituitary lactotrophs in transgenic mice results in selective lactotroph proliferation and adenomas (1995) Endocrinology, 136, pp. 4479-4488
• Borrelli, E., Sawchenko, P.E., Evans, R.M., Pituitary hyperplasia induced by ectopic expression of nerve growth factor (1992) Proc Natl Acad Sci, 89, pp. 2764-2768. , USA
• Fedele, M., Battista, S., Kenyon, L., Baldassarre, G., Fidanza, V., Klein-Szanto, A.J., Parlow, A.F., Fusco, A., Overexpression of the HMGA2 gene in transgenic mice leads to the onset of pituitary adenomas (2002) Oncogene, 21, pp. 3190-3198
• Perumal, P., Vrontakis, M.E., Transgenic mice over-expressing galanin exhibit pituitary adenomas and increased secretion of galanin, prolactin and growth hormone (2003) J Endocrinol, 179, pp. 145-154
• Cai, A., Hayes, J.D., Patel, N., Hyde, J.F., Targeted overexpression of galanin in lactotrophs of transgenic mice induces hyperprolactinemia and pituitary hyperplasia (1999) Endocrinology, 140, pp. 4955-4964
• Ikeda, H., Yoshimoto, T., Shida, N., Miyoshi, I., Nakayama, K., Nakayama, K., Oshima, M., Taketo, M.M., Morphologic and molecular analysis of estrogen-induced pituitary tumorigenesis in targeted disruption of transforming growth factor-beta receptor type II and/or p27 mice (2001) Endocrine, 16, pp. 55-65
• Schuff, K.G., Hentges, S.T., Kelly, M.A., Binart, N., Kelly, P.A., Iuvone, P.M., Asa, S.L., Low, M.J., Lack of prolactin receptor signaling in mice results in lactotroph proliferation and prolactinomas by dopamine-dependent and -independent mechanisms (2002) J Clin Invest, 110, pp. 973-981
• Asa, S.L., Kelly, M.A., Grandy, D.K., Low, M.J., Pituitary lactotroph adenomas develop after prolonged lactotroph hyperplasia in dopamine D2 receptor-deficient mice (1999) Endocrinology, 140, pp. 5348-5355
• Kelly, M.A., Rubinstein, M., Asa, S.L., Zhang, G., Saez, C., Bunzow, J.R., Allen, R.G., Low, M.J., Pituitary lactotroph hyperplasia and chronic hyperprolactinemia in dopamine D2 receptor-deficient mice (1997) Neuron, 19, pp. 103-113
• Kelly, M.A., Rubinstein, M., Phillips, T.J., Lessovn, C.N., Burkhart-Kasch, S., Zhang, G., Bunzow, J.R., Low, M.J., Locomotor activity in D2 dopamine receptor-deficient mice is determined by gene dosage, genetic background, and developmental adaptations (1998) J Neurosci, 18, pp. 3470-3479
• Diaz-Torga, G., Feierstein, C., Libertun, C., Gelman, D., Kelly, M.A., Low, M.J., Rubinstein, M., Becu-Villalobos, D., Disruption of the D2 dopamine receptor alters GH and IGF-I secretion and causes dwarfism in male mice (2002) Endocrinology, 143, pp. 1270-1279
• Hentges, S.T., Low, M.J., Ovarian dependence for pituitary tumorigenesis in D2 dopamine receptor-deficient mice (2002) Endocrinology, 143, pp. 4536-4543
• Basu, S., Nagy, J.A., Pal, S., Vasile, E., Eckelhoefer, I.A., Bliss, V.S., Manseau, E.J., Mukhopadhyay, D., The neurotransmitter dopamine inhibits angiogenesis induced by vascular permeability factor/vascular endothelial growth factor (2001) Nat Med, 7, pp. 569-574
• Chakroborty, D., Sarkar, C., Mitra, R.B., Banerjee, S., Dasgupta, P.S., Basu, S., Depleted dopamine in gastric cancer tissues: Dopamine treatment retards growth of gastric cancer by inhibiting angiogenesis (2004) Clin Cancer Res, 10, pp. 4349-4356
• Banerjee, S.K., Sarkar, D.K., Weston, A.P., De, A., Campbell, D.R., Over expression of vascular endothelial growth factor and its receptor during the development of estrogen-induced rat pituitary tumors may mediate estrogen-initiated tumor angiogenesis (1997) Carcinogenesis, 18, pp. 1155-1161
• Onofri, C., Carbia, N.A., Schaaf, L., Feirer, M., Lohrer, P., Stummer, W., Berner, S., Arzt, E., Estradiol stimulates vascular endothelial growth factor and interleukin-6 in human lactotroph and lactosomatotroph pituitary adenomas (2004) Exp Clin Endocrinol Diabetes, 112, pp. 18-23
• Ferrara, N., Gerber, H., LeCouter, J., The biology of VEGF and its receptors (2003) Nat Med, 9, pp. 669-676
• Ferrara, N., Davis-Smyth, T., The biology of vascular endothelial growth factor (1997) Endocr Rev, 18, pp. 4-25
• Teunis, M.A., Kavelaars, A., Voest, E., Bakker, J.M., Ellenbroek, B.A., Cools, A.R., Heijnen, C.J., Reduced tumor growth, experimental metastasis formation, and angiogenesis in rats with a hyperreactive dopaminergic system (2002) FASEB J, 16, pp. 1465-1467
• Cristina, C., Diaz-Torga, G., Baldi, A., Gongora, A., Rubinstein, M., Low, M.J., Becu-Villalobos, D., Increased pituitary vascular endothelial growth factor-A in dopaminergic D2 receptor knockout female mice (2005) Endocrinology, 146, pp. 2952-2962
• Ochoa, A.L., Mitchner, N.A., Paynter, C.D., Morris, R.E., Ben Jonathan, N., Vascular endothelial growth factor in the rat pituitary: Differential distribution and regulation by estrogen (2000) J Endocrinol, 165, pp. 483-492
• Vidal, S., Kovacs, K., Cohen, S.M., Stefaneanu, L., Lloyd, R.V., Scheithauer, B.W., Localization of vascular endothelial growth factor in non tumorous human pituitaries (1999) Endocr Pathol, 10, pp. 109-122
• Gospodarowicz, D., Abraham, J.A., Schilling, J., Isolation and characterization of a vascular endothelial mitogen produced by pituitary-derived folliculostellate cells (1989) Proc Natl Acad Sci, 86, pp. 7311-7315. , USA
• Fan, L., Iseki, S., Immunohistochemical localization of vascular endothelial growth factor in the endocrine glands of the rat (1998) Arch Histol Cytol, 61, pp. 17-28
• Stojilkovic, S.S., A novel view of the function of pituitary folliculo-stellate cell network (2001) Trends Endocrinol Metab, 12, pp. 378-380
• Gloddek, J., Pagotto, U., Paez, P.M., Arzt, E., Stalla, G.K., Renner, U., Pituitary adenylate cyclase-activating polypeptide, interleukin-6 and glucocorticoids regulate the release of vascular endothelial growth factor in pituitary folliculostellate cells (1999) J Endocrinol, 160, pp. 483-490
• Joseph, F., Younis, N., Haydon, G., Adams, D.H., Wynne, S., Gillet, M.B., Maurice, Y.M., Jones, I.R., Peliosis of the spleen with massive recurrent haemorrhagic ascites, despite splenectomy, and associated with elevated levels of vascular endothelial growth factor (2004) Eur J Gastroenterol Hepatol, 16, pp. 1401-1406
• Park, Y.N., Kim, Y.B., Yang, K.M., Park, C., Increased expression of vascular endothelial growth factor and angiogenesis in the early stage of multistep hepatocarcinogenesis (2000) Arch Pathol Lab Med, 124, pp. 1061-1065
• Wong, A.K., Alfert, M., Castrillon, D.H., Shen, Q., Holash, J., Yancopoulos, G.D., Chin, L., Excessive tumor-elaborated VEGF and its neutralization define a lethal paraneoplastic syndrome (2001) Proc Natl Acad Sci, 98, pp. 7481-7486. , USA
• Vidal, S., Lloyd, R.V., Moya, L., Scheithauer, B.W., Kovacs, K., Expression and distribution of vascular endothelial growth factor receptor Flk-1 in the rat pituitary (2002) J Histochem Cytochem, 50, pp. 533-540
• Yu, R., Ren, S.-G., Horwitz, G.A., Wang, Z., Melmed, S., Pituitary tumor transforming gene (PTTG) regulates placental JEG-3 cell division and survival: Evidence from live cell imaging (2000) Mol Endocrinol, 14, pp. 1137-1146
• Kuchenbauer, F., Theodoropoulou, M., Hopfner, U., Stalla, J., Renner, U., Tonn, J.C., Low, M.J., Paez-Pereda, M., Laminin inhibits lactotroph proliferation and is reduced in early prolactinoma development (2003) Mol Cell Endocrinol, 207, pp. 13-20
• Cristina, C., Achaval-Zaia, R., Baldi, A., Low, M.J., Rubinstein, M., Diaz-Torga, G., Becu-Villalobos, D., Factores de crecimiento en la hiperplasia hipofisaria de ratones hembra deficientes en el receptor dopaminérgico tipo 2 (2000) Medicina, 62, p. 469
• Ezzat, S., Zheng, L., Asa, S.L., Pituitary tumor-derived fibroblast growth factor receptor 4 isoform disrupts neural cell-adhesion molecule/N-cadherin signaling to diminish cell adhesiveness: A mechanism underlying pituitary neoplasia (2004) Mol Endocrinol, 18, pp. 2543-2552
• Bergsland, E.K., Update on clinical trials targeting vascular endothelial growth factor in cancer (2004) Am J Health Syst Pharm, 61, pp. S12-S20
• Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Kabbinavar, F., Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer (2004) N Engl J Med, 350, pp. 2335-2342
• Yamada, S., Takada, K., Angiogenesis in pituitary adenomas (2003) Microsc Res Tech, 60, pp. 236-243
• Lloyd, R.V., Vidal, S., Horvath, E., Kovacs, K., Scheithauer, B., Angiogenesis in normal and neoplastic pituitary tissues (2003) Microsc Res Tech, 60, pp. 244-250

Citas:

---------- APA ----------

---------- CHICAGO ----------

---------- MLA ----------

---------- VANCOUVER ----------